Author of

• 30257

  +

  MA19 - Looking at PROs in Greater Detail - What Patients Actually Want and Expect (ID 147)

  • Event: WCLC 2019
  • Type: Mini Oral Session
  • Track: Treatment in the Real World - Support, Survivorship, Systems Research
  • Presentations: 1
  • Now Available
  • Moderators:Joaquim Bosch-Barrera, Virginia Calvo De Juan
  • Coordinates: 9/10/2019, 11:30 - 13:00, Interlaken (1988)

  • 30265

    +

    MA19.10 - Estimation of Quality-Adjusted Life Expectancy for Stage and Systemic Treatment in Non-Small Cell Lung Cancer in Rajavithi Hospital, Thailand (Now Available) (ID 585)

    11:30 - 13:00  |  Author(s): Oranuch Kamnerdtong
    • Abstract
    • Presentation
    • Slides

    Background
    

    Owing to the high mortality and rapidly growing costs related to lung cancer, it is worth examining the health benefits of treatment in this cancer. This study attempts to quantify the real-life practice quality-adjusted life expectancy (QALE) of non-small cell lung cancer (NSCLC) patients with different stages and systemic treatments.

    Method
    

    This cross-sectional study was conducted by reviewing and collected quality of life (QoL) data from 256 eligible all stages NSCLC patients treated at Rajavithi hospital from May 1^st to October 31^st, 2018. The iSQoL statistical package was used to evaluate QALE compared with the reference Thai population in different stage of disease. For advanced stage, QALE was compared among treatment groups (chemotherapy and Epidermal growth factor receptor tyrosine kinase inhibitors; EGFR TKIs)

    Result
    

    The QALE for patients with early and advanced stage NSCLC were 4.49 ± 0.43 and 1.03 ± 0.08 QALY, with the corresponding loss-of-QALE were 14.02 ± 0.44 and 20.13 ± 0.09 QALY, respectively. The difference of QALE between early and advanced stage was 3.46 QALY (p<0.001).

    Based on systemic treatment in advanced stage, The QALE for patients who received chemotherapy and TKIs were 1.05 ± 0.08 and 2.19 ±0.28 QALY, with the corresponding loss-of-QALE were 20.48 ± 0.09 and 19.12 ± 0.29 QALY, respectively. The difference of QALE between treatment with chemotherapy and TKIs was 1.17 QALY (Figure, p=0.001).

    

    Conclusion
    

    The utility gained from treatment with TKIs in advanced NSCLC is substantial. Early stage had better QALE than advanced stage NSCLC patients.Future study will assess the cost-effectiveness of targeted therapy in Thailand.

    Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.